ALGS News

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

Allegis Launches SafeAxis™ Architectural-Grade Panic Hardware Engineered for Large Industrial Enclosures

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AlgoSec Security Management Solution A33.20 removes network security change friction across hybrid and multi-cloud networks

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

7MM Chronic Hepatitis B Therapeutics Market Drug Forecast and Market Analysis Report 2024-2034: Addressing Unmet Needs, Late-Stage Pipelines and Functional Cure Therapies Drive Growth

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Presents Positive Data at HEP-DART 2025